19 August 2025 - Bristol Myers Squibb Canada today announced that Health Canada has approved Opdivo (nivolumab) in combination with Yervoy (ipilimumab) for the first-line treatment of adult patients with:

• unresectable or metastatic microsatellite instability-high or mismatch repair deficient colorectal cancer
• unresectable or advanced hepatocellular carcinoma

This dual immunotherapy regimen offers a new first-line treatment approach for two challenging gastro-intestinal cancers, supported by two pivotal Phase 3 trials: CheckMate-8HW in colorectal cancer which demonstrated improvement in progression-free survival, and CheckMate-9DW in hepatocellular carcer which showed improvements in survival—each compared to existing standard therapies.

Read BMS press release